Healthcare Market Research Company in Spain

BioNixus is a leading healthcare market research company in Spain, delivering HCP surveys in Spanish, SNS payer landscape research, KOL mapping at Spanish university hospitals, and bilingual (Spanish/English) outputs aligned with AEMPS, CIPM, and Autonomous Community requirements. BioNixus combines primary research depth with physician access across all 17 Autonomous Communities.

A healthcare market research company in Spain designs and executes studies covering physician prescribing behaviour, SNS payer and Autonomous Community formulary dynamics, patient journeys, KOL influence mapping at Spanish university hospitals, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies operating in Spain's decentralised, SNS-funded healthcare market.

Spain's SNS provides universal coverage through 17 independent Autonomous Communities, each managing its own healthcare budget and formulary decisions — creating the most decentralised payer landscape in the EU5. National CIPM pricing and SNS reimbursement decisions do not guarantee regional uptake; Catalonia (CatSalut), Madrid (SERMAS), and Andalucía (SAS) each apply additional formulary criteria. The GENESIS pharmacoeconomic evaluation system, used by Spanish hospital pharmacy committees, adds a unique institutional evidence layer not found in Germany, France, Italy, or the UK.

BioNixus covers oncology, immunology and biologics (including biosimilar dynamics in Spain's SNS), cardiovascular (SEC guidelines), rheumatology (SER), rare disease (AEMPS special access pathways), respiratory, infectious disease, neurology, diabetes and metabolic, medical devices, and consumer health across the Spanish market — with bilingual Spanish/English execution throughout.

Yes. BioNixus maintains verified physician and specialist networks across Spain's major university hospitals including Hospital Clínic Barcelona, Hospital Universitari Vall d'Hebron, Hospital Universitario La Paz (Madrid), Hospital Universitario 12 de Octubre (Madrid), Hospital Universitario Virgen del Rocío (Seville), and Clínica Universidad de Navarra. For scarce specialties such as oncology or rare disease, we recruit through Spanish specialist society networks (SEOM, SEMI, SER, SEC) and Autonomous Community hospital networks.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including CIPM payer depth interviews and Autonomous Community formulary mapping typically run 6–10 weeks depending on therapy area and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across key communities (Catalonia, Madrid, Andalucía) may require extended planning timelines.

Yes. BioNixus designs and executes Spanish patient research in full compliance with GDPR (EU General Data Protection Regulation) and applicable Spanish data protection law (Ley Orgánica de Protección de Datos / LOPDGDD). All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling procedures aligned with Spanish research ethics standards.

Yes. Spanish modules can run with comparable cells in Germany, France, Italy, the UK (EU5), the USA, Canada, Japan, Australia, and other markets — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.